trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Schizophrenia and bipolar disorder can sometimes remit and are not always lifelong

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Schizophrenia and bipolar disorder are heterogeneous conditions in which many individuals achieve periods of clinical or functional remission rather than experiencing continuous, lifelong impairment.

The analysis

The retrieved literature contains multiple studies investigating remission, functional recovery, and treatment tapering or discontinuation in schizophrenia and bipolar disorder (e.g., papers 6, 9, and 11), supporting the claim that these conditions can remit and are not universally lifelong without interruption.

Evidence for · 3
Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia.
Recorded source metadata

Lu C, Dong Y, Zhai Z, Gao T, Luo M, Chang D, Chen J, Xue J, Zhao Y, Xiang Q, Li X, Ma X, Wei Z, Feng T, Liu D. Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia.. 2026. https://doi.org/10.1017/s0033291726104024

This study identifies patient subgroups with schizophrenia who achieve sustained functional remission and good outcomes following antipsychotic discontinuation.

See more details
More for · 2
Persistent Psychosis During 4 Years after First Hospitalization for a Psychotic Disorder in the Suffolk County Mental Health Project: Prevalence, Risk Factors, and Relationship to 25-Year Outcomes.
Recorded source metadata

Rubio JM, Lian W, Bromet EJ, Guinart D, Kotov R, Correll CU, Jonas K. Persistent Psychosis During 4 Years after First Hospitalization for a Psychotic Disorder in the Suffolk County Mental Health Project: Prevalence, Risk Factors, and Relationship to 25-Year Outcomes.. 2026. https://doi.org/10.1093/schbul/sbag049

The 25-year study notes that while early persistent psychosis is linked to poorer long-term outcomes, it indicates that variability exists and not all cases follow a strictly non-remitting path.

DREAMSPHEN: a randomised controlled study comparing dose reduction of antipsychotics vs maintenance treatment in schizophrenia spectrum disorder after stratification based on patients' psychotic phenotype - study protocol of a personalised medicine approach.
Recorded source metadata

Berna F, Horowitz MA, Javelot H, Meyer N, Foucher JR. DREAMSPHEN: a randomised controlled study comparing dose reduction of antipsychotics vs maintenance treatment in schizophrenia spectrum disorder after stratification based on patients' psychotic phenotype - study protocol of a personalised medicine approach.. 2026. https://doi.org/10.1136/bmjopen-2026-117593

This trial protocol investigates dose reduction and tapering in clinically stabilized patients with schizophrenia spectrum disorder who have achieved symptom remission.

The paper trail · every fact has a biography
first checked01 Aug 2026
judged → SUPPORTED · 7701 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt